Deltagen Inc. (DGEN) Stock Price & Analysis
Deltagen Inc. (DGEN) closed at USD 0 on Thursday, October 22, 2026, up 0.00% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 0; the Oct 22, 2026 session ranged USD 0–0 on volume of 442,968 shares. Market capitalization is $2.75M, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, retrieved October 23, 2026 at 22:54 UTC.
Also available as compact Markdown for AI agents: nexqual.com/DGEN.md
Key facts (DGEN)
- Analysts: None.
- Total return with dividends: 1Y +0.0% vs S&P 500 +13.4%; 5Y +0.0% vs S&P 500 +76.9%.
Analysts (DGEN)
Consensus None.
Total return (dividends reinvested) (DGEN)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +0.0% | +0.0% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +0.0% | +0.0% |
| Volatility (annualized) | 0.0% | 0.0% |
| Max drawdown | +0.0% (→) | +0.0% (→) |
DGEN analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter | — | — | — | $0 | — |
| Next quarter | — | — | — | $0 | — |
| Current fiscal year | — | — | — | $0 | — |
| Next fiscal year | — | — | — | $0 | — |
Key Statistics (as of October 23, 2026 at 22:54 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 442,968 shares |
| Market Cap | $2.75M |
| Exchange | PNK |
Technical Analysis (DGEN)
Nexqual's technical model rates DGEN "STRONG SELL" based on 0 bullish and 5 bearish signals across 126 daily candles, as of October 23, 2026 at 22:54 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (DGEN)
Wall Street analysts rate DGEN "None", per Nexqual as of October 23, 2026 at 22:54 UTC.
| Consensus Rating | None |
|---|
Earnings (DGEN)
Source: Nexqual, October 23, 2026 at 22:54 UTC.
Financials & Fundamentals (DGEN)
| Total Revenue | $770,000 |
|---|---|
| Gross Margin | +99.48% |
| Operating Margin | +29.28% |
| Profit Margin | -5.97% |
| ROE | -2.72% |
| Debt / Equity | 0.01 |
| Current Ratio | 1.45 |
| Total Cash | $23,000 |
| Total Debt | $25,000 |
Source: Nexqual, October 23, 2026 at 22:54 UTC.
Financial Health Score (DGEN)
Nexqual rates Deltagen Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 22:54 UTC.
| Growth | Strong — Revenue +376% YoY (annual) |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Strong — $23K cash, no debt |
| Cash Flow | Solid — Operating cash flow $24K (TTM) |
| Efficiency | Critical — ROE -3%, ROA -1.6% |
Ownership (DGEN)
| Shares Outstanding | 0 |
|---|
Source: Nexqual, October 23, 2026 at 22:54 UTC.
Leadership (DGEN)
Deltagen Inc. is led by Robert J. Driscoll, CEO, President, Secretary & Director, per Nexqual as of October 23, 2026 at 22:54 UTC.
| CEO, President, Secretary & Director | Robert J. Driscoll |
|---|---|
| Chief Financial Officer | Daniel Ratto |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| KMTS | Kestra Medical Technologies, Lt | USD 28.76 | ▲ 1.55% |
| XRAY | DENTSPLY SIRONA Inc. | USD 9.43 | ▼ 0.74% |
| LMAT | LeMaitre Vascular, Inc. | USD 84.45 | ▼ 1.03% |
| ATRC | AtriCure, Inc. | USD 58.97 | ▼ 0.56% |
| WRBY | Warby Parker Inc. | USD 25.91 | ▲ 0.93% |
| PLSE | Pulse Biosciences, Inc | USD 53.02 | ▲ 0.65% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 22:54 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt